Alnylam Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
ALNY
CUSIP
02043Q107
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 02043Q107 since 12/18/2024, newest first.

Filer % of Class Filed
Capital World Investors 13G/A Amendment 3 8.2% 5/14/2026
Event 3/31/2026
Capital Research Global Investors 13G/A Amendment 1 7.1% 5/14/2026
Event 3/31/2026
FMR LLC 13G/A Amendment 23
11.0% 5/6/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.4% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 10 0% 3/26/2026
Event 3/13/2026
FMR LLC 13G/A Amendment 22
12.8% 11/5/2025
Event 9/30/2025
Vanguard Group Inc 13G/A Amendment 9 10.0% 4/7/2025
Event 3/31/2025
Capital Research Global Investors 13G 5.4% 2/13/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 23 52.3 k $12.9 M
2026 Q2 839 194 M $42.6 B
2026 Q1 834 131 M $43.4 B
2025 Q4 908 134 M $53.2 B
2025 Q3 879 138 M $61.3 B
2025 Q2 704 134 M $43.3 B
2025 Q1 690 131 M $34.9 B
2024 Q4 645 129 M $30.1 B
2024 Q3 623 128 M $34.7 B
2024 Q2 593 123 M $29.8 B
2024 Q1 570 118 M $17.6 B
2023 Q4 553 121 M $23.2 B
2023 Q3 509 118 M $20.9 B
2023 Q2 514 119 M $22.6 B
2023 Q1 518 120 M $24.0 B
2022 Q4 539 123 M $29.2 B
2022 Q3 537 134 M $26.9 B
2022 Q2 477 114 M $16.6 B
2022 Q1 486 116 M $19.0 B
2021 Q4 478 112 M $19.0 B
2021 Q3 436 112 M $21.1 B
2021 Q2 452 112 M $19.1 B
2021 Q1 425 109 M $15.4 B
2020 Q4 423 109 M $14.1 B
2020 Q3 402 109 M $15.8 B
2020 Q2 414 112 M $16.6 B
2020 Q1 377 109 M $11.8 B
2019 Q4 357 107 M $12.4 B
2019 Q3 320 109 M $8.80 B
2019 Q2 335 107 M $7.75 B
2019 Q1 324 96.9 M $9.06 B
2018 Q4 322 93.5 M $6.81 B
2018 Q3 359 92.6 M $8.11 B
2018 Q2 349 92.0 M $9.06 B
2018 Q1 329 92.1 M $11.0 B
2017 Q4 317 92.2 M $11.7 B
2017 Q3 284 87.6 M $10.3 B
2017 Q2 254 87.2 M $6.95 B
2017 Q1 229 83.0 M $4.26 B
2016 Q4 238 80.7 M $3.02 B
2016 Q3 286 77.6 M $5.26 B
2016 Q2 277 74.3 M $4.14 B
2016 Q1 278 72.1 M $4.45 B
2015 Q4 279 66.7 M $6.30 B
2015 Q3 277 65.5 M $5.26 B
2015 Q2 300 65.6 M $7.86 B
2015 Q1 256 64.5 M $6.73 B
2014 Q4 232 58.6 M $5.71 B
2014 Q3 200 59.0 M $4.61 B
2014 Q2 215 59.3 M $3.74 B
2014 Q1 222 55.7 M $3.74 B